How Are Bristol-Myers Squibb’s Revenues, Expenses & Profits Likely To Change Over The Next Five Years?
We have created an interactive dashboard on how Bristol-Myers Squibb’s (NYSE:BMY) revenues, expenses, and profits are expected to change over the next five years. You can adjust the expected segment-wise revenue and margin forecasts, and see its impact on the profitability, and earnings.
- We do not expect significant changes in revenues in 2022, as compared to 2017, as the growth in the company’s oncology segment will likely be offset by a decline in virology, immunology, and mature drugs sales. Note that the patents for many drugs within these segments have expired, and they now face – or will face – biosimilar competition.
Expected Change In Operating Expenses By Division Between 2017 and 2022
- Operating expenses are expected to decline slightly by around $400 million, as higher expenses at oncology will be offset by other segments, that will face revenue decline during 2017-2022.
- Should You Pick Bristol Myers Squibb Stock After A 30% Fall Last Year And Q4 Beat?
- Is Bristol Myers Squibb Stock Undervalued At $50?
- Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level of $80?
- Which Stock Is A Better Healthcare Pick – Bristol Myers Squibb Or HCA?
- Will Bristol Myers Squibb Stock Rise Post Q1?
- Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer?
- The gross profit for the company is expected to increase slightly by $170 million. Note that the increase in gross profits at the oncology segment is forecast at over $2.5 billion, which will be offset by declines at the virology, immunology, and mature drugs segments.
- We estimate BMY’s pharmaceuticals gross profit margin will remain stable at 73% over the next five years.
- This should translate into gross profits of over $15 billion for the company in the coming years.
- Gross profits will likely remain in the range of $15-16 billion, as there is no significant change expected in revenues.
Our price estimate of $60 for Bristol Myers Squibb implies a discount of over 10% to the market.
What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs
For CFOs and Finance Teams | Product, R&D, and Marketing Teams
Like our charts? Explore example interactive dashboards and create your own